Brief: Advicenne's Sibnayal® Accepted For Use Within NHS Scotland

Advicenne SA

14/09/2022 06:07

Sept 14 (Reuters) - Advicenne SA  ALDVI.PA :
    * ADVICENNE UPDATES ON AVAILABILITY OF SIBNAYAL® TO PATIENTS
AND
CAREGIVERS IN GREAT BRITAIN
    * SIBNAYAL® HAS BEEN ACCEPTED FOR USE WITHIN NHS SCOTLAND
    * IN ENGLAND, ADVICENNE HAS WITHDRAWN ITS SUBMISSION TO
NATIONAL
INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)
    * CURRENT ABSENCE OF LONG-TERM OUTCOME DATA FOR DRTA
PATIENTS
PRECLUDED A ROBUST HEALTH ECONOMIC MODEL TO BE PROVIDED TO NICE
    * IN ENGLAND, ADVICENNE WILL WORK DIRECTLY WITH SPECIALIST
CENTERS
TO MAKE SIBNAYAL AVAILABLE TO TREAT DRTA PATIENTS
    * ADVICENNE BELIEVES THAT ECONOMIC IMPACT OF THIS DECISION
WILL BE
LIMITED
    * PLANS TO COLLECT DATA THAT WILL SUPPORT A NEW SUBMISSION
TO NICE
AND PROVIDE NECESSARY LONG-TERM OUTCOMES DATA.

Source text for Eikon:  ID:nBw2lyGDYa 
Further company coverage:  ALDVI.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))